Published on 9 Feb 2024 on Zacks via Yahoo Finance
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
The fourth-quarter earnings season entered its last lap this week, with Eli Lilly LLY and AstraZeneca AZN announcing their fourth-quarter and full-year 2023 results. Novo Nordisk NVO, Merck MRK and Novartis NVS made M&A announcements.
Recap of the Week’s Most Important Stories
Lilly & AstraZeneca Announce Q4 Earnings: Lilly’s fourth-quarter results were better than expected as it beat estimates for earnings as well as sales. The company witnessed strong sales growth of Mounjaro, Verzenio, Jardiance and Taltz, which made up for the decline in the sales of Trulicity in the quarter.